Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

New research suggests that drugs like Ozempic may provide more health benefits than previously thought. These medications, ...

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...

US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...